Cargando…

Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing

Measuring total cell-free DNA (cfDNA) or cancer-specific mutations herein has presented as new tools in aiding the treatment of cancer patients. Studies show that total cfDNA bears prognostic value in metastatic colorectal cancer (mCRC) and that measuring cancer-specific mutations could supplement b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Demuth, Christina, Spindler, Karen-Lise Garm, Johansen, Julia S., Pallisgaard, Niels, Nielsen, Dorte, Hogdall, Estrid, Vittrup, Benny, Sorensen, Boe Sandahl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2018
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085225/ https://www.ncbi.nlm.nih.gov/pubmed/30086420 http://dx.doi.org/10.1016/j.tranon.2018.07.013

Ejemplares similares

Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
por: Spindler, Karen Lise Garm, et al.
Publicado: (2015)

Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer
por: Lyskjær, Iben, et al.
Publicado: (2019)

MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability
por: Boisen, Mogens Karsbøl, et al.
Publicado: (2015)

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
por: Skougaard, Kristin, et al.
Publicado: (2014)

miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3(rd) Line Cetuximab and Irinotecan
por: Schou, Jakob V., et al.
Publicado: (2014)

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2017)

A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations
por: Demuth, Christina, et al.
Publicado: (2018)

Systematic review: brain metastases from colorectal cancer—Incidence and patient characteristics
por: Christensen, Troels Dreier, et al.
Publicado: (2016)

Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection
por: Dong, Lianhua, et al.
Publicado: (2018)

Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer
por: Spindler, Karen-Lise Garm, et al.
Publicado: (2023)

The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients
por: Bønløkke, Sara, et al.
Publicado: (2022)

Next Generation Sequencing Technology in the Clinic and Its Challenges
por: Vestergaard, Lau K., et al.
Publicado: (2021)

Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients
por: Winther-Larsen, Anne, et al.
Publicado: (2017)

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2020)

Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
por: Spindler, K-L G, et al.
Publicado: (2014)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2016)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment
por: Demuth, Christina, et al.
Publicado: (2017)

Detection of circulating KRAS mutant DNA in extracellular vesicles using droplet digital PCR in patients with colon cancer
por: Choi, Jeesoo, et al.
Publicado: (2022)

Circulating cell-free DNA as predictor of pathological complete response in locally advanced rectal cancer patients undergoing preoperative chemoradiotherapy
por: Truelsen, Christina Glismand, et al.
Publicado: (2022)

Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing
por: Holm, Matilda, et al.
Publicado: (2020)

Detection of KRAS G12D in colorectal cancer stool by droplet digital PCR
por: Olmedillas-López, Susana, et al.
Publicado: (2017)

Expression Stability Analysis of Candidate References for Normalization of RT-qPCR Data Using RefSeeker R package
por: Petersen, Patrick H.D., et al.
Publicado: (2023)

Time for a lead-time definition? Author response to ‘Why the length of recurrence free survival or “lead-times” can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis’
por: Spindler, Karen-Lise Garm, et al.
Publicado: (2023)

Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40
por: DAUGAARD, SØREN, et al.
Publicado: (2009)

Circulating Antinuclear Antibodies in Patients with Pelvic Masses Are Associated with Malignancy and Decreased Survival
por: Heegaard, Niels H. H., et al.
Publicado: (2012)

KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients
por: Olmedillas López, Susana, et al.
Publicado: (2016)

The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus
por: Lefèvre, Anna C., et al.
Publicado: (2021)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
por: Spindler, Karen-Lise G, et al.
Publicado: (2011)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
por: Boisen, Mogens K., et al.
Publicado: (2014)

A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
por: Theile, Susann, et al.
Publicado: (2022)

Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells
por: Clement, Michelle Simone, et al.
Publicado: (2020)

cGAS-STING pathway expression as a prognostic tool in NSCLC
por: Raaby Gammelgaard, Kristine, et al.
Publicado: (2021)

miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer
por: Nielsen, Boye Schnack, et al.
Publicado: (2014)

EGFR transcription in non‐small‐cell lung cancer tumours can be revealed in ctDNA by cell‐free chromatin immunoprecipitation (cfChIP)
por: Månsson, Christoffer Trier, et al.
Publicado: (2021)

Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group
por: Callesen, Louise Bach, et al.
Publicado: (2023)

Cell‐free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients
por: Trier Maansson, Christoffer, et al.
Publicado: (2023)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol
por: Spindler, Nicklas Juel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tam2t44lil96t76asf3v6pk4a3